RICHMOND, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (NASDAQ:TSPT) today announced that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, at 2:10 p.m. Eastern Standard Time. A live audio webcast and replay of the presentation will be available on the Transcept investor webpage at http://www.transcept.com/. About Transcept Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States. For further information, please visit the company's website at: http://www.transcept.com/. Contact: Transcept Pharmaceuticals, Inc. Greg Mann Director, Corporate Communications (510) 215-3567 DATASOURCE: Transcept Pharmaceuticals, Inc. CONTACT: Greg Mann, Director, Corporate Communications of Transcept Pharmaceuticals, Inc., +1-510-215-3567, Web Site: http://www.transcept.com/

Copyright